Venus Remedies has received patent for vancoplus product, one of the key research product of Venus used to combat Methilicillin Resistant Staphylococcus Aureus (MRSA), from Replublic of South Africa and New Zealand. Vancoplus is a brand of ceftriaxone and vancomycin along with chemical vector used in CVMC technology which has a potential to restrict production of toxin produced by MRSA. Vancoplus therapy reduces treatment time and cost and is a boon for medical field.

Vancoplus has been successfully launched in few markets globally and has achieved a sales of US$ 3.5 million in three years. The product is under registration in many countries. The patent for Vancoplus is valid till February 2026 in both the countries. The patent of this product has also been filed in US, Canada, Europe, Ukraine, Russia, etc besides India and the grant is expected to be received soon.

The pharmaceutical market size of South Africa was worth US$ 3.03 billion in 2007 and that it should reach $4.41 billion by 2012 and the current size of the New Zealand pharmaceutical market is US$ 379 million. Venus hope to reap a good share of profits and huge business out of this research mile stone. The company is planning to soon enter into these markets with CTD dossier of this product and has already initiated talks with some big MNCs for out licensing in territories where patent has been granted for this product.

MRSA infection has become increasingly difficult to treat, and can lead to death. Most MRSA infections occur in wounds (e.g. surgical wounds), skin (e.g. intravenous access sites), or in the bloodstream or in brain. He organism possesses several properties that contribute to its ability to cause serious disease, including the production of toxins that prove fatal. Vancoplus is the only remedy after vaccination (used for prevention and not for cure) to treat MRSA and multi-drug resistant microbes causing meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin structure infections and staphylococcal endocarditis.

Baseline data from the Pan-European Antimicrobial Resistance Using Local Surveillance (PEARLS) study of 1001-2002 showed that South Africa had a MRSA prevalence of 33.3 per cent. The African 'meningitis belt' – which includes all or part of 21 countries, ha reported more than seven lakh cases of meningitis (an infection of the fluid in the spinal cord and the fluid that surrounds the brain) over the past decade. Roughly 10-20 per cent of persons infected die, and one out of five survivors is likely to suffer from a permanent disability such as hearing loss, mental retardation, or paralysis. Vancoplus is an ideal therapy for bacterial meningitis and other bacterial infections. Meningococcal disease is responsible for about 1.35 lakh deaths globally each year, with over one million cases.